ArticleBone marrow transplantation2000
Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome).
Article in Bone marrow transplantation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Patient-driven surveys of mucopolysaccharidoses revealed patient-reported outcomes in the Japan MPS patient and family group.Orphanet journal of rare diseases · 2026Article
- Merging evans syndrome with mucopolysaccharidosis type II: a case report.Frontiers in pediatrics · 2026Article
- Assessment of Activity of Daily Life in Mucopolysaccharidosis Type II Patients with Hematopoietic Stem Cell Transplantation.Diagnostics (Basel, Switzerland) · 2020Article
- Recent trends in mucopolysaccharidosis research.Journal of human genetics · 2019Review
- Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Article
- Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.Drug design, development and therapy · 2017Review
- Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche.Bone marrow research · 2011Article
- In utero transplantation of monocytic cells in cats with alpha-mannosidosis.Transplantation · 2009Article
- Adult stem cells and their trans-differentiation potential--perspectives and therapeutic applications.Journal of molecular medicine (Berlin, Germany) · 2008Review
- Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases.Springer seminars in immunopathology · 2004Review
- Review
- Ethical considerations in allogeneic hematopoietic cell transplantation for children with slowly fatal conditions.Bone marrow transplantation · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hunter syndrome is an X-linked metabolic storage disorder arising from deficiency of iduronate sulfatase enzyme activity. Despite the successful use of hematopoietic cell transplantation for a variety of lysosomal and peroxisomal storage diseases, limited benefit occurs following transplantation in either the severe or mild forms of Hunter syndrome. A brief ethical commentary is provided on the case of a boy with mucopolysaccharidosis IIB (ie the mild form) who received an unrelated umbilical cord blood transplant to improve his future quality of life. Bone Marrow Transplantation (2000).
Indexed as
Identifiers
10828872What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.